Gilder Gagnon Howe & Co. LLC Acquires Shares of 34,339 Allakos Inc (ALLK)

Gilder Gagnon Howe & Co. LLC acquired a new stake in shares of Allakos Inc (NASDAQ:ALLK) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 34,339 shares of the company’s stock, valued at approximately $1,545,000.

Separately, Strs Ohio bought a new stake in Allakos during the 3rd quarter valued at about $107,000. 0.10% of the stock is owned by institutional investors and hedge funds.

A number of analysts have weighed in on ALLK shares. Zacks Investment Research upgraded shares of Allakos from a “hold” rating to a “buy” rating and set a $38.00 price objective for the company in a research note on Monday, October 15th. Goldman Sachs Group started coverage on shares of Allakos in a research note on Monday, August 13th. They set a “neutral” rating and a $31.00 price objective for the company. William Blair started coverage on shares of Allakos in a research note on Monday, August 13th. They set an “outperform” rating for the company. Finally, Jefferies Financial Group started coverage on shares of Allakos in a research note on Monday, August 13th. They set a “buy” rating and a $53.00 price objective for the company.

Shares of ALLK stock opened at $51.85 on Friday. Allakos Inc has a 52 week low of $26.00 and a 52 week high of $52.59.

Allakos (NASDAQ:ALLK) last announced its quarterly earnings results on Wednesday, August 29th. The company reported ($4.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($3.90). On average, equities analysts expect that Allakos Inc will post -1.07 EPS for the current fiscal year.

Allakos Company Profile

Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.

Featured Article: What is the Ex-Dividend Date in Investing?

Want to see what other hedge funds are holding ALLK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allakos Inc (NASDAQ:ALLK).

Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply